Heart Failure: Advanced Imaging and New Treatments

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425).

Deadline for manuscript submissions: 30 September 2026 | Viewed by 1963

Special Issue Editors


E-Mail Website
Guest Editor Assistant
Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy
Interests: minimally invasive cardiac care; heart failure; heart valve disease; echocardiography; intensive cardiac care; Marfan syndrome
Special Issues, Collections and Topics in MDPI journals

E-Mail
Guest Editor Assistant
Intensive Cardiac Care Unit, “San Giuseppe Moscati” Hospital, ASL CE, 81031 Aversa, Italy
Interests: echocardiography; heart failure; heart valve disease; atrial fibrillation

Special Issue Information

Dear Colleagues,

Heart failure remains a major global health challenge with increasing incidence and a significant impact on patients’ quality of life. This Special Issue will gather cutting-edge contributions spanning from diagnostics to therapeutic innovations. We invite manuscripts that delve into the applications and clinical impacts of advanced imaging techniques, such as strain echocardiography, quantitative cardiac magnetic resonance, and cardiac PET, in the early assessment of myocardial dysfunction, risk stratification, and monitoring treatment response. We are particularly interested in articles exploring novel pharmacological treatments, including SGLT2 inhibitors, GLP-1 receptor agonists, and other emerging therapies that are revolutionizing the prognosis of heart failure. We also wish to include research on non-pharmacological approaches, such as new device implantation strategies and cellular and gene therapies. Our aim is to create a comprehensive and stimulating resource that fosters research and improves the care of patients suffering from heart failure.

Prof. Dr. Antonello D’Andrea
Guest Editor

Dr. Alfredo Mauriello
Dr. Adriana Correra
Guest Editor Assistants

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • biomarkers
  • cardiomyopathies
  • device therapy
  • echocardiography
  • imaging, arrythmias
  • cardiac rehabilitation
  • heart valve disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

15 pages, 2606 KB  
Systematic Review
Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
by Benjamin J. Behers, Christian Sanchez, Omar Hozayen, Yousef Hozayen, Rheiner Kammer, William T. Corrigan, Christoph A. Stephenson-Moe, Matthew W. Miller, Mohab Idriss, Luis E. Cekan, Alan D. King, Garrett H. Brown and Karen M. Hamad
J. Cardiovasc. Dev. Dis. 2026, 13(2), 103; https://doi.org/10.3390/jcdd13020103 - 21 Feb 2026
Cited by 1 | Viewed by 1549
Abstract
Heart failure with preserved ejection fraction (HFpEF) affects 32 million people worldwide and is responsible for tens of billions of dollars in healthcare expenditure annually, with costs primarily driven by hospitalizations. HFpEF is notoriously difficult to treat, but emerging studies suggest that glucagon-like [...] Read more.
Heart failure with preserved ejection fraction (HFpEF) affects 32 million people worldwide and is responsible for tens of billions of dollars in healthcare expenditure annually, with costs primarily driven by hospitalizations. HFpEF is notoriously difficult to treat, but emerging studies suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be effective therapies. We performed a systematic review and meta-analysis of six randomized controlled trials with 5564 total participants investigating GLP-1 RAs in patients with HFpEF. Overall, no significant effect was noted for GLP-1 RAs on our primary outcomes of cardiovascular mortality and worsening heart failure (HF) events, although they were associated with improvement in quality of life measures. Furthermore, safety data favored the GLP-1 RA group, although tolerability did not differ compared with placebo. While the pooled analysis of all GLP-1 RAs showed neutral effects versus hard endpoints, sensitivity analyses excluding older-generation agents (exenatide) revealed a significant 41% reduction in HF events, suggesting that newer, more potent agents (semaglutide, tirzepatide) may offer disease-modifying benefits in HFpEF. Although future studies are needed, GLP-1 RAs appear to be promising for the treatment of HFpEF. Full article
(This article belongs to the Special Issue Heart Failure: Advanced Imaging and New Treatments)
Show Figures

Graphical abstract

Back to TopTop